神经活性类固醇对中枢神经系统损伤保护机制的研究进展

顾雪, 毛定安

中国当代儿科杂志 ›› 2009, Vol. 11 ›› Issue (07) : 606-609.

PDF(1031 KB)
PDF(1031 KB)
中国当代儿科杂志 ›› 2009, Vol. 11 ›› Issue (07) : 606-609.
综述

神经活性类固醇对中枢神经系统损伤保护机制的研究进展

  • 顾雪,毛定安
作者信息 +

Research progress on the mechanism of protection of neuroactive steroids against central lesions

  • GU Xue, MAO Ding-An
Author information +
文章历史 +

引用本文

导出引用
顾雪, 毛定安. 神经活性类固醇对中枢神经系统损伤保护机制的研究进展[J]. 中国当代儿科杂志. 2009, 11(07): 606-609
GU Xue, MAO Ding-An. Research progress on the mechanism of protection of neuroactive steroids against central lesions[J]. Chinese Journal of Contemporary Pediatrics. 2009, 11(07): 606-609
中图分类号: R74   

参考文献

[1]Hosie AM, Wilkins ME, da Silva HM, Smart TG. Endogenous neurosteroids regulate GABAA receptors through two discrete transmembrane sites[J]. Nature, 2006, 444(7118): 486-489.
[2]Lambert JJ, Belelli D, Peden DR. Neurosteroid modulation of GABAA receptors [J]. Prog Neurobol, 2003, 71(1): 67-80.
[3]Morrow AL. Recent developments in the significance and therapeutic relevance of neuroactive steroids-introduction to the special issue [J]. Pharmacol Ther, 2007, 116(1): 1-6.
[4]杨萍萍. 神经活性类固醇作用机制及应用前景 [J]. 生命的化学, 2001, 21(2): 114-116.
[5]来艳萍, 刘燕强. γ-氨基丁酸A型受体在神经精神性疾病发生发展中的意义 [J]. 中国临床药理学与治疗, 2008, 13(2): 208-212.
[6]Frank C, Sagratella S. Neuroprotective effects of allopregnenolone on hippocampal irreversible neurotoxicity in vitro [J]. Prog Neuropsychopharmacol Biol Psychiatry, 2000, 24(7):1117-1126.
[7]Patchev VK, Montkowski A, Rouskova D. Neonatal treatment of rats with the neuroactive steroid tetrahydro-deoxycorticosterone (THDOC) abolishes the behavioral and neuroendocrine consequences of adverse early life events [J]. 1997, 99(5):962-966.
[8]Reddy DS. Pharmacology of endogenous neuroactive steroids [J]. Crit Rev Neurobiol, 2003, 15(3):197-234.
[9]Cottrell GA, Lambert JJ, Peters JA. Modulation of GBAA receptor activity by alphaxalone[J]. Br J Pharmacol, 1987, 90(3):491-500.
[10]Qiu S, Hua YL, Yang F, Chen YZ, Luo JH. Subunit assembly of N-methyl-d-aspartate receptors analyzed by fluorescence resonance energy transfer[J]. J Biol Chem, 2005, 280(26):24923-24930.
[11]Pallarés M, Darnaudéry M, Day J, Le Moal M, Mayo M. The neurosteroid pregneolone sulfate infused into the nucleus basalis increases both acetylcholine release in the frontal cortex or amygdale and spatial memory[J]. Neuroscience, 1998, 87(3):551-558.
[12]Sadri-Vakili G, Johnson DW, Janis GC, Gibbs TT, Pierce RC, Farb DH. Inhibition of NMDA-induced striatal dopamine release and behavioral activation by the neuroactive steroid 3a-hydroxy-5β-pregnan-20-one hemisuccinate[J]. J Neurochem, 2003, 86(1): 92-101.
[13]Shirakawa H, Katsuki H, Kume T. Regulation of N-methyl-D-aspartate cytotoxicity by neuroactive steroids in rat cortical neurons[J]. Eur J Pharmacol, 2002, 454(2-3):165-175.
[14]Owens MJ, Ritchie JC, Nemeroff CB. 5 alpha-pregnane-3alpha, 21-diol-20-one (THDOC) attenuates mild stress-induced increases in plasma corticosterone via a non-glucocorticoid mechanism: comparison with alprazolam[J]. Brain Res, 1992, 57(3):353-355.
[15]Patchev VK, Shoaib M, Holsboer F, Almeida OF. The neurosteroid tetrahydroprogesterone counteracts corticotropinreleasing hormoneinduced anxiety and alters the release and gene expression of corticotropin-releasing hormone in the rat hypothalamus[J]. Neuroscience, 1994, 62(1):265-271.
[16]Patchev VK, Hassan AH, Holsboer DF, Almeidao FX. The neurosteroid tetrahydroprogesterone attenuates the endocrine response to stress and exerts glucocorticoid-like effects on vasopressin gene transcription in the rat hypothalamus[J]. Neuropsychopharmacology, 1996, 15(6):533-540.
[17]Patchev VK, Montkowski A, Rouskova D, Koranyi L, Holsboer F, Almeida O. Neonatal treatment of rats with the neuroactive steroid tetrahydrodeoxycorticosterone (THDOC) abolishes the behavioral and neuroendocrine consequences of adverse early life events[J]. J Clin Invest, 1997, 99(5):962-966.
[18]Biggio F, Gorini G, Caria S, Murrul L, Mostallino MC, Sanna E, et al. Plastic neuronal changes in GABA(A) receptor gene expression induced by progesterone metabolites: in vitro molecular and functional studies[J]. Pharmacol Biochem Behav, 2006, 84(4):545-554.
[19]Mellon SH. Neurosteroid regulation of central nervous system development[J]. Pharmacol Ther, 2007, 116(1):107-124.
[20]Donley MP, Schulkin J, Rosen JB. Glucocorticoid receptor antagonism in the basolateral amygdala and ventral hippocampus interferes with longterm memory of contextual fear[J]. Behaw Brain Res, 2005, 164(2):197-205.
[21]Schumacher M, Guennoun R, Stein DG, De Nicola AF. Progesterone: therapeutic opportunities for neuroprotection and myelin repair[J]. Pharmacol Ther, 2007, 116(1):77-106.
[22]Cameron SA, Dutia MB. Lesion-induced plasticity in rat vestibular nucleus neurones dependent on glucocorticoid receptor activation [J]. J Physiol, 1999, 518( Pt 1):151-158.
[23]Wiedemann K, Hirschmann M, Knaudt K, Rupprecht R, Seier FE, Holsboer F. Sleep endocrine effects of megestrol acetate in healthy men [J]. J Neuroendocrinol, 1998, 10(9):719-727.
[24]Shirakawa H, Katsuki H, Kume T. Pregnenolone sulphate attenuates AMPA cytotoxicity on rat cortical neurons[J]. Eur J Neurosci, 2005, 21(9):2329-2335.


PDF(1031 KB)

Accesses

Citation

Detail

段落导航
相关文章

/